biostudies-literatureUnknown24(11)Chrysant SGHypertension is particularly prevalent in patients aged ≥65 years, those with a body mass index ≥30 kg m(-2), Blacks and those with type II diabetes. Here we report a prespecified secondary analysis of the efficacy of amlodipine (10 mg day(-1)), olmesartan medoxomil (40 mg day(-1)), a combination of the two and placebo in these subgroups. Patients were randomized to treatment for 8 weeks. The primary efficacy endpoint was the change from baseline in mean seated diastolic blood pressure (DBP). Secondary efficacy endpoints included the change from baseline in mean seated systolic BP (SBP), proportions of patients achieving BP goal (<140/90 mm Hg or <130/80 mm Hg in patients with diabetes), and the number and percentage of patients achieving a range of BP targets. Safety and tolerability of aJournal of human hypertension730-8https://www.ebi.ac.uk/biostudies/studies/S-EPMC2963900biostudies-literatureEfficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension.PMC2963900Melino MLee JHeyrman RChrysant SGKarki SfalseEfficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension.Hypertension is particularly prevalent in patients aged ≥65 years, those with a body mass index ≥30 kg m(-2), Blacks and those with type II diabetes. Here we report a prespecified secondary analysis of the efficacy of amlodipine (10 mg day(-1)), olmesartan medoxomil (40 mg day(-1)), a combination of the two and placebo in these subgroups. Patients were randomized to treatment for 8 weeks. The primary efficacy endpoint was the change from baseline in mean seated diastolic blood pressure (DBP). Secondary efficacy endpoints included the change from baseline in mean seated systolic BP (SBP), proportions of patients achieving BP goal (<140/90 mm Hg or <130/80 mm Hg in patients with diabetes), and the number and percentage of patients achieving a range of BP targets. Safety and tolerability of a2010-01-01T00:00:00Z2010 Nov2025-04-26T11:33:21.216Z2019-03-27T00:35:07ZS-EPMC29639002016484710.1038/jhh.2010.5